Cancer patients whose clinical trial participation helps drug makers commercialize new therapies shouldn’t have to pay for those lifesaving drugs, an oncologist argues.
On the cancer ward, patients’ addiction fears and their need for pain relief inevitably intersect. Oncologist Mikkael Sekeres, MD, MS, shares one experience.
An oncologist on why we should drop the penias and pathics in favor of plain language when we talk to patients.
Data from 15 centers in the U.S. and Europe indicate that immunosuppressive therapy should be used more frequently in patients with myelodysplastic syndromes.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
An international team of researchers recently finished a phase 3 clinical trial to test the anemia drug luspatercept on patients with myelodysplastic syndromes.
Study leads to FDA-approval of ivosidenib for patients with relapsed or refractory acute myeloid leukemia that have the genetic mutation IDH1.
The overall program will cover important advances in the treatment of hematologic malignancies including mantle cell lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL) and more.
Sometimes, what matters most to patients matters more than anything medical we have to offer.
It’s time to end overly restrictive eligibility criteria for cancer clinical trials, says Mikkael Sekeres, MD, MS. A new study offers a first step.
Dr. Sekeres offers concrete measures toward a repaired relationship between Contract Research Organizations and scientific investigators.